Multiple lines of evidence support the hypothesis that over-activation of FGF19/FGFR4 pathway, as well as FGF19, FGFR4 and KLB gene amplifications, may promote HCC growth, malignant progression, metastasis and drug resistance [73–76]. Here, FGFR4 is linked to hepatocellular carcinoma.